Toujeo Dosing and Administration
Administer Toujeo (insulin glargine 300 U/mL) subcutaneously once daily at the same time each day into the abdomen, thigh, or deltoid, with individualized dosing based on metabolic needs and glucose monitoring. 1
Administration Guidelines
Route and Timing
- Inject subcutaneously once daily at any time during the day, but maintain consistency with the same time each day 1
- Rotate injection sites (abdomen, thigh, deltoid) to reduce risk of lipodystrophy and localized cutaneous amyloidosis 1
- Do not dilute or mix with any other insulin or solution 1
- Available only in prefilled pens (1.5 mL SoloStar and 3 mL Max SoloStar) to minimize dosing errors 1
Starting Dose in Type 2 Diabetes
- Initial dose: 0.2 units/kg body weight for insulin-naïve patients 2
- This aligns with the FDA-approved approach of individualizing based on metabolic needs 1
Dose Titration
Use structured titration algorithms targeting fasting blood glucose (FBG):
- Target FBG range: 90-130 mg/dL for most patients 2
- Alternative target: 110-150 mg/dL for patients requiring less aggressive control 2
- Titrate over weeks to months based on FBG monitoring 2
- In simulation studies, 93% of patients achieved target FBG within 3 months using algorithmic titration 2
Critical Dosing Considerations
Concentration Differences
Toujeo (U-300) is NOT bioequivalent to Lantus (U-100) - this is a critical safety point:
- U-300 glargine has a longer duration of action (>24 hours) and flatter pharmacokinetic profile than U-100 3, 4
- Higher daily doses required with Gla-300 compared to Gla-100 to achieve equivalent glycemic control 4, 5
- When switching from U-100 to U-300, expect to need dose adjustments upward 4
Monitoring Requirements
- Closely monitor glucose when initiating and during the first several weeks 1
- Increase monitoring frequency with any changes to insulin regimen, concomitant medications, meal patterns, or physical activity 1
- Enhanced monitoring needed in patients with renal/hepatic impairment or hypoglycemia unawareness 1
Safety Profile
Hypoglycemia Risk
- Lower nocturnal hypoglycemia risk compared to NPH and potentially U-100 glargine, particularly in type 2 diabetes 5
- In type 1 diabetes, hypoglycemia rates are comparable between U-100 and U-300 formulations 5
- Minimal hypoglycemia observed in titration studies (3-4% of patients) 2
Common Pitfalls to Avoid
- Never share pens between patients, even with needle changes 1
- Check insulin labels before each injection to prevent accidental mix-ups with other insulin products 1
- Do not use U-100 syringes with concentrated insulins 3
- Monitor potassium levels in at-risk patients (hypokalemia can be life-threatening) 1
Integration with Other Therapies
Type 2 Diabetes
- Can be combined with 1-2 oral hypoglycemic agents 6
- If additional prandial coverage needed, add rapid-acting insulin at largest meal (start with 4 units or 10% of basal dose) 3
Type 1 Diabetes
- Use as part of basal-bolus regimen with prandial insulin 3
- The prolonged >24-hour duration ensures full daily coverage with once-daily dosing 7
Contraindications
- During episodes of hypoglycemia 1
- Hypersensitivity to insulin glargine or excipients 1
- Not recommended for diabetic ketoacidosis 1
Drug Interactions
Adjust insulin dosage when using drugs affecting glucose metabolism, including beta-blockers (which may mask hypoglycemia symptoms) 1. Monitor for fluid retention when combining with thiazolidinediones 1.